ETF Holdings Breakdown of IOVA

News associated with IOVA

After Hours Most Active for Jun 6, 2025 : IOVA, NVDA, INTC, ACHR, AAL, CSX, AAPL, NKE, PCG, BAC, MRK, PFE

The NASDAQ 100 After Hours Indicator is up 14.86 to 21,776.65. The total After hours volume is currently 96,255,289 shares traded.The following are the most active stocks for the after hours session: Iovance Biotherapeutics, Inc. (IOVA) is +0.02 at $2.07, with 5,435,272 shares t - 2025-06-06 20:24:57

Ameriprise Financial Inc. Has $463,000 Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Ameriprise Financial Inc. lessened its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 88.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 62,548 shares of the biotechnology company’s stock after selling 494,986 shares during the period. Ameriprise Financial Inc.’s holdings in Iovance Biotherapeutics […] - 2025-06-05 07:22:52

Captrust Financial Advisors Cuts Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Captrust Financial Advisors lowered its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 42.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 28,738 shares of the biotechnology company’s stock after selling 20,868 shares during the period. Captrust Financial Advisors’ […] - 2025-05-23 07:47:02

Iovance Biotherapeutics (NASDAQ:IOVA) Rating Lowered to “Neutral” at UBS Group

UBS Group lowered shares of Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) from a buy rating to a neutral rating in a report issued on Friday morning, Marketbeat.com reports. UBS Group currently has $2.00 price target on the biotechnology company’s stock, down from their prior price target of $17.00. Other equities research analysts also recently issued […] - 2025-05-19 05:46:52

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 5.4% Following Analyst Downgrade

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report)’s share price fell 5.4% during mid-day trading on Tuesday after The Goldman Sachs Group lowered their price target on the stock from $16.00 to $8.00. The Goldman Sachs Group currently has a buy rating on the stock. Iovance Biotherapeutics traded as low as $1.85 and last traded […] - 2025-05-15 05:39:11

Iovance Biotherapeutics (NASDAQ:IOVA) Downgraded by Truist Financial to Hold

Truist Financial cut shares of Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) from a buy rating to a hold rating in a research report sent to investors on Monday morning, MarketBeat.com reports. A number of other equities research analysts also recently weighed in on the company. Chardan Capital lowered their price target on Iovance Biotherapeutics from […] - 2025-05-13 05:56:46

Pre-Market Most Active for May 9, 2025 : TSLL, SQQQ, TQQQ, QBTS, IOVA, WOLF, NVDA, IBIT, DNB, UMC, HIMS, AEG

The NASDAQ 100 Pre-Market Indicator is up 91.45 to 20,155.02. The total Pre-Market volume is currently 99,990,466 shares traded.The following are the most active stocks for the pre-market session: Direxion Daily TSLA Bull 2X Shares (TSLL) is +0.2 at $10.57, with 10,864,676 share - 2025-05-09 12:28:55

First Trust Advisors LP Invests $2.40 Million in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

First Trust Advisors LP acquired a new position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 324,246 shares of the biotechnology company’s stock, valued at approximately $2,399,000. A number of other institutional investors also […] - 2025-05-05 08:10:51

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Stock Holdings Lessened by CANADA LIFE ASSURANCE Co

CANADA LIFE ASSURANCE Co cut its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 5.7% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 57,265 shares of the biotechnology company’s stock after selling 3,484 shares during the period. CANADA LIFE ASSURANCE Co’s holdings […] - 2025-05-01 08:38:58

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Stake Raised by Invesco Ltd.

Invesco Ltd. lifted its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 2.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 221,928 shares of the biotechnology company’s stock after acquiring an additional 4,967 shares during the quarter. Invesco Ltd.’s holdings in Iovance Biotherapeutics were worth $1,642,000 at the end of the most […] - 2025-04-30 07:46:52

After Hours Most Active for Apr 25, 2025 : NVDA, CMG, MSFT, IOVA, XOM, LNW, CMCSA, NU, TSLA, MP, PFE, NEE

The NASDAQ 100 After Hours Indicator is up 13.65 to 19,446.21. The total After hours volume is currently 107,054,554 shares traded.The following are the most active stocks for the after hours session: NVIDIA Corporation (NVDA) is -0.12 at $110.89, with 5,366,088 shares traded. A - 2025-04-25 20:29:54

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 5.9% Following Analyst Downgrade

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report)’s stock price dropped 5.9% during trading on Tuesday after Barclays lowered their price target on the stock from $22.00 to $5.00. Barclays currently has an overweight rating on the stock. Iovance Biotherapeutics traded as low as $3.20 and last traded at $3.21. Approximately 3,959,691 shares traded hands […] - 2025-04-17 05:15:02

Geode Capital Management LLC Buys 222,425 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Geode Capital Management LLC boosted its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 3.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,871,420 shares of the biotechnology company’s stock after purchasing an additional 222,425 shares during the quarter. Geode Capital Management […] - 2025-04-15 08:33:09

Wellington Management Group LLP Sells 12,056 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Wellington Management Group LLP reduced its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 9.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 117,426 shares of the biotechnology company’s stock after selling 12,056 shares during the quarter. […] - 2025-04-14 07:50:56

Prudential Financial Inc. Has $235,000 Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Prudential Financial Inc. boosted its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 83.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,700 shares of the biotechnology company’s stock after acquiring an additional 14,452 shares during the quarter. Prudential Financial […] - 2025-04-11 08:44:52

American Century Companies Inc. Sells 72,020 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

American Century Companies Inc. trimmed its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 36.3% in the 4th quarter, Holdings Channel reports. The fund owned 126,654 shares of the biotechnology company’s stock after selling 72,020 shares during the quarter. American Century Companies Inc.’s holdings in Iovance Biotherapeutics were worth $937,000 as of its […] - 2025-04-11 07:37:05

Mitsubishi UFJ Asset Management Co. Ltd. Acquires 4,192 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 16.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 29,684 shares of the biotechnology company’s stock after acquiring an additional 4,192 shares during […] - 2025-04-04 08:12:59

Sei Investments Co. Grows Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Sei Investments Co. raised its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 1.9% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 478,481 shares of the biotechnology company’s stock after purchasing an additional 8,965 shares during the period. Sei Investments Co.’s holdings in Iovance Biotherapeutics were worth $3,541,000 as of its […] - 2025-04-04 07:34:52

Teacher Retirement System of Texas Acquires 13,895 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Teacher Retirement System of Texas grew its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 28.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 63,025 shares of the biotechnology company’s stock after purchasing an additional 13,895 shares during the period. Teacher Retirement System […] - 2025-04-01 07:40:45

Raymond James Financial Inc. Invests $11.57 Million in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Raymond James Financial Inc. acquired a new position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 1,563,296 shares of the biotechnology company’s stock, valued at approximately $11,568,000. Other institutional investors and hedge funds have also recently modified their holdings of the company. SBI Securities Co. Ltd. […] - 2025-03-21 08:34:50

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $20.25 Average Price Target from Analysts

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month […] - 2025-03-21 05:34:49

US Bancorp DE Sells 7,158 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

US Bancorp DE reduced its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 36.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 12,497 shares of the biotechnology company’s stock after selling 7,158 shares during the quarter. US Bancorp DE’s holdings in Iovance Biotherapeutics were worth $92,000 at the end […] - 2025-03-18 07:11:01

Bank of New York Mellon Corp Purchases 23,865 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Bank of New York Mellon Corp raised its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 2.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 865,834 shares of the biotechnology company’s stock after buying an additional 23,865 shares during the quarter. Bank of New York Mellon Corp’s holdings in Iovance […] - 2025-03-17 07:10:48

Chardan Capital Issues Pessimistic Forecast for Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price

Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) had its target price decreased by equities researchers at Chardan Capital from $34.00 to $30.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. IOVA has been the topic of several other research reports. Piper Sandler […] - 2025-03-05 10:09:00

Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Cut to $19.00 by Analysts at The Goldman Sachs Group

Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) had its price target cut by The Goldman Sachs Group from $22.00 to $19.00 in a report issued on Monday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. A number of other research analysts have also recently commented on the company. Chardan Capital lowered their […] - 2025-03-04 08:58:47

Iovance Biotherapeutics (NASDAQ:IOVA) Given New $15.00 Price Target at Truist Financial

Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) had its price objective trimmed by Truist Financial from $25.00 to $15.00 in a research note issued to investors on Monday morning,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. Other equities analysts have also issued reports about the stock. Chardan Capital reduced their […] - 2025-03-04 08:22:47

New York State Common Retirement Fund Sells 98,840 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

New York State Common Retirement Fund trimmed its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 8.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 1,121,417 shares of the biotechnology company’s stock after selling 98,840 shares during the quarter. New York State […] - 2025-02-26 09:36:58

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $21.07 Consensus Price Target from Brokerages

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) has been given an average rating of “Moderate Buy” by the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price […] - 2025-02-24 06:48:53

Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 1-Year Low on Analyst Downgrade

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) shares hit a new 52-week low during trading on Monday after Piper Sandler lowered their price target on the stock from $10.00 to $7.50. Piper Sandler currently has a neutral rating on the stock. Iovance Biotherapeutics traded as low as $5.52 and last traded at $5.68, with […] - 2025-02-05 06:20:54

IOVA institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	142,071	USD 247,204
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	19,754	USD 34,372
2025-06-26	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	348,318	USD 606,073
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	169,532	USD 294,986
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	169,532	USD 294,986
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	1,553	USD 2,702
Total =		850,760	USD 1,480,323

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer